Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs + ECP for High-Risk/Steroid-Refractory Acute GVHD
NCT05333029Phase 2Withdrawn
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in Acute Graft-Versus-Host Disease (aGvHD). Planned start Oct 2024; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT05333029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333029.